Compare Gilead Sciences, Inc. (GILD) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Gilead Sciences, Inc. trades at $149.49 (market cap $182.40B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $60.42 (market cap $77.43B). The key difference: Gilead Sciences, Inc. is far larger — about 2.4× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and MONDELEZ INTERNATIONAL INC Common Stock for 107 Days on average.
| GILD | MDLZ | |
|---|---|---|
Market Cap | $182.40B | $77.43B |
Volume | 4,469,821 | 7,695,104 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $64.99 |
52-Week Low | $116.74 | $51.51 |
Typical Hold Time | 111 Days | 107 Days |
Enterprise Value | $205.46B | $97.78B |
Dividend Yield | 2.23% | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Mondelez International (MDLZ) trades at $59.38, down 0.4% with a bearish technical signal despite beating earnings expectations for three consecutive quarters. The company maintains solid fundamentals with $38.54B revenue, 8.86% net margin, and strong analyst support (76% buy ratings). Recent developments include a dividend increase to $0.52 per share and new product launches like Toblerone Diamond Truffles.
MDLZ presents a compelling long-term opportunity with attractive valuation metrics (P/E 22.22) and 14% upside to consensus price target of $70.29. Key risks include cocoa cost pressures and competitive snack market dynamics, but the company's global brand strength and consistent execution support bullish outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
